



Supplemental figure 1. Forest plot of the incidence of radiotherapy-induced mucositis (Grade 2) (honey vs. control intervention)



Supplemental figure 2. Forest plot of the incidence of severe pain after radiotherapy (honey vs. control intervention)




Supplemental figure 3. Percentage risk of bias in the included studies


Study	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Amanat 2017	+	+	?	?	+	+	+
Bardy 2012	+	+	+	+	+	?	+
Biswal 2003	+	+	?	?	+	+	+
Charalambous 2017	+	+	+	+	+	+	+
Charalambous 2018	+	+	+	+	+	+	+
Hawley 2013	+	+	+	+	+	+	+
Jayachandran 2012	+	-	?	?	+	+	+
Khanal 2010	+	+	?	?	+	+	+
Morallebnejad 2008	+	?	-	+	+	+	+
Rao 2017	+	+	+	+	+	+	+
Rashad 2009	-	?	?	?	+	+	?
Samdarivya 2015	+	+	+	+	-	+	-

Supplemental figure 4. Types of potential bias in the included studies


Grade 1




Grade 2



Grade 3



Grade 4



Supplemental figure 5. Analysis of publish bias by funnel plot in different grade of mucositis.

Supplement table 1.

**Characteristics of patients and trials associated with honey treatment arm vs control arm**

	OR,95%(CI)	Heterogeneity
<b>Age</b>	-0.71 (-2.87, 1.45)	Chi <sup>2</sup> = 1.57, P = 0.95, I <sup>2</sup> = 0%
<b>Sex</b>		
Overall results	1.01 (0.78, 1.30)	Chi <sup>2</sup> = 25.60, P = 0.08; I <sup>2</sup> = 34%
male	1.34 (0.94, 1.91)	Chi <sup>2</sup> = 10.42, P = 0.24; I <sup>2</sup> = 23%
female	0.78(0.54,1.11)	Chi <sup>2</sup> = 10.73, P = 0.22; I <sup>2</sup> = 25%
<b>Tumor location</b>		
Overall results	0.92(0.70,1.20)	Chi <sup>2</sup> = 10.88, P = 0.90, I <sup>2</sup> = 0%
Oral cavity	0.85 [0.55, 1.30]	Chi <sup>2</sup> = 1.87, P = 0.87, I <sup>2</sup> = 0%
Oropharynx+ hypopharynx	0.96 [0.64, 1.44]	Chi <sup>2</sup> = 3.98, P = 0.55, I <sup>2</sup> = 0%
Nasopharynx cavity	1.57(0.66,3.72)	Chi <sup>2</sup> = 1.20, P = 0.55, I <sup>2</sup> = 0%
Others	0.49(0.17,1.44)	Chi <sup>2</sup> = 1.17, P = 0.76, I <sup>2</sup> = 0%

Supplement table 2.

**Subgroup analysis for the of the mild mucositis between honey vs. control intervention**

Outcome and subgroups	participants	OR,95%(CI)	Heterogeneti (I <sup>2</sup> and P)	
<b>County</b>				
Overall results	79/97	0.71(0.49,1.05)	I <sup>2</sup> =78%	P<0.01
Aisa	47/66	0.60(0.38,0.95)	I <sup>2</sup> =82%	P<0.01
Non-Asia	32/31	1.12(0.54,2.33)	I <sup>2</sup> =2%	P=0.31
<b>mucositis cause</b>				
Overall results	79/97	0.71(0.49,1.05)	I <sup>2</sup> =78%	P<0.01
Radiotherapy	38/38	1.00(0.57,1.74)	I <sup>2</sup> =87%	P<0.01
Radiotherapy + chemotherapy	41/59	0.52(0.31,0.90)	I <sup>2</sup> =74%	P=0.01
<b>Radiation dose</b>				
Overall results	79/97	0.71(0.49,1.05)	I <sup>2</sup> =78%	P<0.001
<60Gy	78/81	0.94(0.62,1.42)	I <sup>2</sup> =76%	P<0.001
≥60Gy	1/16	0.04(0.00,0.29)	--	--
<b>Assessment scale</b>				
Overall results	79/97	0.71(0.49,1.05)	I <sup>2</sup> =78%	P<0.01
WHO	11/23	0.29(0.11,0.73)	I <sup>2</sup> =68%	P=0.08
RTOG	68/74	0.87(0.57,1.34)	I <sup>2</sup> =87%	P<0.01
<b>Control arm</b>				
Overall results	79/97	0.71(0.49,1.05)	I <sup>2</sup> =78%	P<0.001
placebo	26/23	1.45(0.59,3.56)	--	--
saline	25/58	0.28(0.15,0.49)	I <sup>2</sup> =67%	P=0.003
other	28/16	2.43(1.13,5.23)	I <sup>2</sup> =84%	P=0.002

Supplement table 3.

**Subgroup analysis for the of the severe mucositis between honey vs. control intervention**

Outcome and subgroups	participants	OR,95%(CI)	Heterogeneti (I <sup>2</sup> and P)	
<b>County</b>				
Overall results	79/145	0.30(0.20,0.44)	I <sup>2</sup> =78%	P<0.01
Asia	14/80	0.10(0.05,0.19)	I <sup>2</sup> =56%	P=0.04
Non-Asia	65/65	0.98(0.54,1.80)	I <sup>2</sup> =12%	P=0.29
<b>mucositis cause</b>				
Overall results	79/145	0.30(0.20,0.44)	I <sup>2</sup> =73%	P<0.01
Radiotherapy	56/89	0.32(0.18,0.54)	I <sup>2</sup> =84%	P<0.01
Radiotherapy + chemotherapy	23/56	0.28(0.15,0.50)	I <sup>2</sup> =73%	P=0.01
<b>Radiation dose</b>				
Overall results	79/145	0.30(0.20,0.44)	I <sup>2</sup> =78%	P<0.01
<60Gy	52/66	0.47(0.25,0.90)	I <sup>2</sup> =93%	P<0.01
≥60Gy	27.79	0.22(0.13,0.37)	I <sup>2</sup> =67%	P<0.01
<b>Assessment scale</b>				
Overall results	79/145	0.30(0.20,0.44)	I <sup>2</sup> =78%	P<0.01
WHO	2/22	0.04(0.01,0.19)	I <sup>2</sup> =0%	P=0.92
RTOG	77/123	0.37(0.24,0.56)	I <sup>2</sup> =77%	P<0.01
<b>Control arm</b>				
Overall results	79/145	0.30(0.20,0.44)	I <sup>2</sup> =78%	P<0.01
placebo	65/65	0.98(0.54,1.80)	I <sup>2</sup> =12%	P=0.29
saline	13/53	0.14(0.07,0.28)	I <sup>2</sup> =68%	P=0.02
other	1/27	0.03(0.01,0.17)	I <sup>2</sup> =0%	P=0.75